These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26418899)

  • 1. BPTF promotes tumor growth and predicts poor prognosis in lung adenocarcinomas.
    Dai M; Lu JJ; Guo W; Yu W; Wang Q; Tang R; Tang Z; Xiao Y; Li Z; Sun W; Sun X; Qin Y; Huang W; Deng WG; Wu T
    Oncotarget; 2015 Oct; 6(32):33878-92. PubMed ID: 26418899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.
    Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W
    Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of bromodomain PHD finger transcription factor in ovarian cancer and its critical role for cancer cell proliferation and survival.
    Miao J; Zhang M; Huang X; Xu L; Tang R; Wang H; Han S
    Biochem Cell Biol; 2021 Jun; 99(3):304-312. PubMed ID: 32985220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-3666 inhibits lung cancer cell proliferation, migration, and invasiveness by targeting BPTF.
    Pan L; Tang Z; Pan L; Tang R
    Biochem Cell Biol; 2019 Aug; 97(4):415-422. PubMed ID: 30481052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.
    Wang J; Zou K; Feng X; Chen M; Li C; Tang R; Xuan Y; Luo M; Chen W; Qiu H; Qin G; Li Y; Zhang C; Xiao B; Kang L; Kang T; Huang W; Yu X; Wu X; Deng W
    Mol Cancer; 2017 Oct; 16(1):158. PubMed ID: 29025423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling.
    Fu L; Shi K; Wang J; Chen W; Shi D; Tian Y; Guo W; Yu W; Xiao X; Kang T; Wang S; Huang W; Deng W
    Mol Cancer; 2014 Apr; 13():89. PubMed ID: 24766673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell lung cancer.
    Xu J; Wang Q; Leung ELH; Li Y; Fan X; Wu Q; Yao X; Liu L
    Front Med; 2020 Feb; 14(1):60-67. PubMed ID: 31104301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of TGF-β signaling blockade on human A549 lung adenocarcinoma cell lines.
    Xu CC; Wu LM; Sun W; Zhang N; Chen WS; Fu XN
    Mol Med Rep; 2011; 4(5):1007-15. PubMed ID: 21725601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small interference RNA targeting tissue factor inhibits human lung adenocarcinoma growth in vitro and in vivo.
    Xu C; Gui Q; Chen W; Wu L; Sun W; Zhang N; Xu Q; Wang J; Fu X
    J Exp Clin Cancer Res; 2011 May; 30(1):63. PubMed ID: 21619686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
    Zhang C; Chen L; Liu Y; Huang J; Liu A; Xu Y; Shen Y; He H; Xu D
    Theranostics; 2021; 11(8):3676-3693. PubMed ID: 33664855
    [No Abstract]   [Full Text] [Related]  

  • 11. BPTF biomarker correlates with poor survival in human NSCLC.
    Gong YC; Liu DC; Li XP; Dai SP
    Eur Rev Med Pharmacol Sci; 2017 Jan; 21(1):102-107. PubMed ID: 28121349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
    Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
    J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting regulation of VEGF by BPTF in non-small cell lung cancer and its potential clinical significance.
    Dai M; Hua C; Wang M; Gao L; Jiang L; Liu Y
    Eur J Med Res; 2022 Dec; 27(1):299. PubMed ID: 36529788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CREB-binding protein regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathway.
    Tang Z; Yu W; Zhang C; Zhao S; Yu Z; Xiao X; Tang R; Xuan Y; Yang W; Hao J; Xu T; Zhang Q; Huang W; Deng W; Guo W
    Mol Oncol; 2016 Feb; 10(2):317-29. PubMed ID: 26628108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bmi-1-shRNA inhibits the proliferation of lung adenocarcinoma cells by blocking the G1/S phase through decreasing cyclin D1 and increasing p21/p27 levels.
    Zheng X; Wang Y; Liu B; Liu C; Liu D; Zhu J; Yang C; Yan J; Liao X; Meng X; Yang H
    Nucleic Acid Ther; 2014 Jun; 24(3):210-6. PubMed ID: 24552182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling.
    Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y
    Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 19. Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
    Bircan HA; Gurbuz N; Pataer A; Caner A; Kahraman N; Bayraktar E; Bayraktar R; Erdogan MA; Kabil N; Ozpolat B
    Lung Cancer; 2018 Oct; 124():31-39. PubMed ID: 30268477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2.
    Cai F; Zhu Q; Miao Y; Shen S; Su X; Shi Y
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):59-69. PubMed ID: 27629878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.